BSN Capital's Q4 Filing Is a High-Conviction Bet: NVIDIA at 21.8% ($2.12B AUM)
BSN Capital Partners reported a compact 24-position portfolio with NVIDIA at 21.8% ($463.5M) and top-5 concentration above 61%. AUM corrected to $2.12B.
BSN Capital Partners Ltd filed one of the clearest high-conviction portfolios this quarter: only 24 holdings, with NVIDIA at 21.8% and top-5 concentration at 61.4%.
TL;DR
- AUM: $2.12B (corrected from prior error).
- Holdings: 24 positions.
- Top-1: NVDA at 21.8% ($463.5M).
- Top-5: 61.4% in NVDA, MSFT, IVV, BRK/B, AAPL.
- QoQ shift: AUM surged from $0.30B (Q3) to $2.12B (Q4)—a 7x increase.
- Signal: This is a thesis portfolio, not a closet index.
Filing Snapshot
| Filer | BSN Capital Partners Ltd |
|---|---|
| Quarter | 2025Q4 |
| AUM | $2.12B |
| Holdings | 24 |
| Top Names | NVDA (21.8%), MSFT (11.9%), IVV (11.6%), BRK/B (9.3%) |
The High-Conviction Thesis
BSN Capital's Q4 filing reveals a deliberate concentration strategy. With only 24 holdings and NVIDIA alone representing $463.5M (21.8% of AUM), this is not a diversified mandate. The top-5 holdings account for $1.3B, or 61.4% of the entire portfolio.
This level of concentration is intentional. Managers who run thesis-driven portfolios accept higher tracking error in exchange for conviction bets. The question is not whether concentration is risky—it is—but whether the manager has the skill and conviction to justify it.
What Analysts Might Misread
A concentrated filing is not automatically bearish or reckless. In many cases, concentration is the intended design: fewer names, tighter thesis control, and explicit acceptance of tracking error.
The real test is next-quarter behavior. If the manager keeps adding around the same core names, it is conviction. If concentration drops suddenly without redeployment clarity, that's regime change. Watch for whether NVDA stays above 20% in Q1 2026.
Sector Composition
The portfolio is heavily tilted toward technology and financial services. NVIDIA, Microsoft, Apple, Amazon, and Netflix together represent 54.6% of AUM. This is a bet on AI infrastructure and cloud computing dominance.
The inclusion of IVV (iShares Core S&P 500 ETF) at 11.6% is notable—it suggests the manager is hedging concentration risk with a broad index position, or using it as a cash-equivalent placeholder.
How to Use This on 13F Insight
- Bookmark BSN Capital Partners to track quarterly concentration changes.
- Compare this filing against other high-conviction funds to understand concentration benchmarks.
- Set a watchlist alert for NVDA to monitor if BSN Capital increases or decreases its position next quarter.
- Review the Q1 2026 filing to confirm whether this concentration is sustained or reduced.
Q&A
Is 21.8% in one stock too high?
For diversified mandates, yes. For high-conviction strategies, it is within acceptable bounds if the manager has demonstrated skill. The risk is real, but so is the potential upside if the thesis is correct.
Why does top-5 share matter more than holdings count?
Because P&L impact is dominated by capital weights, not line-item count. A 24-position portfolio with 61% in the top-5 is effectively a 5-position portfolio with a long tail of smaller bets.
What is the cleanest follow-up metric?
Quarterly change in top-1 and top-5 concentration. If both stay stable or increase, conviction is confirmed. If both drop sharply, the thesis may have changed.
What would invalidate the thesis?
A sharp reduction in core names without a coherent replacement basket, or a shift to lower-conviction names. Watch the Q1 2026 filing closely.
Related Research
Explore all researchPartners Value Investments L.P. reported a $10.70B book for 2025Q4 with BN and BAM absorbing nearly all of the economic weight. It is a useful example of how a corporate-family filing can still deliver a very strong concentration signal.
Brookfield Corp /ON/ reported an $80.76B 13F book for 2025Q4, and Brookfield Asset Management dominated the filing at 77.4% of weight. The remaining positions matter, but they read more like supporting pieces than co-equal bets.
Lilly Endowment reported an $84.52B 13F portfolio for 2026Q1, and every dollar of it still sat in Eli Lilly. The filing is unusually simple, which is exactly why it makes such a strong case study in institutional concentration.
The most useful 2025Q4 question was not just who owned the biggest stocks. It was which large managers rotated the hardest beneath the surface. This scoreboard compares four major 13F portfolios side by side.
A five-filer comparison shows why Berkshire looked like a conviction allocator while the giant diversified managers kept much broader top books in 2025Q4.